XFOR vs. CMPX, ELEV, ABOS, IPHA, OPT, CRDF, KOD, IPSC, ADVM, and CHRS
Should you be buying X4 Pharmaceuticals stock or one of its competitors? The main competitors of X4 Pharmaceuticals include Compass Therapeutics (CMPX), Elevation Oncology (ELEV), Acumen Pharmaceuticals (ABOS), Innate Pharma (IPHA), Opthea (OPT), Cardiff Oncology (CRDF), Kodiak Sciences (KOD), Century Therapeutics (IPSC), Adverum Biotechnologies (ADVM), and Coherus BioSciences (CHRS). These companies are all part of the "biological products, except diagnostic" industry.
X4 Pharmaceuticals (NASDAQ:XFOR) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, community ranking, media sentiment and analyst recommendations.
72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 1.1% of X4 Pharmaceuticals shares are held by insiders. Comparatively, 30.0% of Compass Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Compass Therapeutics is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
X4 Pharmaceuticals has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.
Compass Therapeutics' return on equity of -26.07% beat X4 Pharmaceuticals' return on equity.
X4 Pharmaceuticals currently has a consensus price target of $3.00, indicating a potential upside of 126.42%. Compass Therapeutics has a consensus price target of $9.00, indicating a potential upside of 488.24%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Compass Therapeutics is more favorable than X4 Pharmaceuticals.
X4 Pharmaceuticals received 47 more outperform votes than Compass Therapeutics when rated by MarketBeat users. However, 71.88% of users gave Compass Therapeutics an outperform vote while only 65.42% of users gave X4 Pharmaceuticals an outperform vote.
In the previous week, Compass Therapeutics had 2 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 4 mentions for Compass Therapeutics and 2 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 0.77 beat Compass Therapeutics' score of 0.15 indicating that X4 Pharmaceuticals is being referred to more favorably in the media.
Summary
Compass Therapeutics beats X4 Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
Get X4 Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XFOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
X4 Pharmaceuticals Competitors List
Related Companies and Tools
